Company Overview
Snapshot
Founded in March 2022 by Albert Kashchenevsky, Eyecuracy operates with 1–10 employees. The company has raised $1.3 million across one funding round from one investor, Random Forest VC. Eyecuracy is currently in the clinical trial phase for its diagnostic and monitoring platform for neurological and neuro-ophthalmological disorders.
Business overview
Eyecuracy develops a hybrid healthcare platform for the diagnostics, monitoring, and treatment of neurological and neuro-ophthalmological disorders. Its core technology features a user-friendly hardware device, a smart cloud service, and proprietary AI algorithms for accurate eye tracking. The platform aims to provide convenient and cost-effective patient care through in-office diagnosis, home monitoring, and therapy, addressing challenges in traditional diagnostic methods. Eyecuracy serves the healthcare industry, specifically targeting hospitals and healthcare providers with its SaaS, computer vision, and machine learning solutions for eye diseases and remote monitoring in markets across Europe, North America, and Asia.
Log in to access full profile ›Company Intelligence Q&A
- Who founded Eyecuracy?
- Eyecuracy was founded by Albert Kashchenevsky, who serves as the CEO.
- What is Eyecuracy's primary focus?
- Eyecuracy focuses on developing an AI-powered eye tracking platform for the diagnosis, monitoring, and treatment of neurological and neuro-ophthalmological disorders.
- What is the current product stage of Eyecuracy's solution?
- Eyecuracy's solution is currently in the clinical trial stage, where it is being tested for its diagnostic and monitoring capabilities for neurological and neuro-ophthalmological disorders.
- Which markets does Eyecuracy target?
- Eyecuracy targets geomarkets in Europe, North America, and Asia with its healthcare solutions.
- What is Eyecuracy's competitive advantage in eye tracking?
- Eyecuracy's advantage lies in its unique AI-powered eye tracking algorithm, which accurately locates the optical axis by going to the cornea perimeter (the limbus) and using innovative AI data analysis, unlike other commercially available solutions that rely on infrared cornea reflections.